These in vivo findings indicate that treatment with adavosertib and panobinostat alone or in combination with MI are effective therapies worthy of further in vivo testing and development in AML with mtNPM1 with or without FLT3-ITD. The gene discussed is FLT3; the disease is acute myeloid leukemia.